About us
History of Equaly
Equaly was founded on the discovery that some innate immune responses are, in fact, antigen-specific. Being able to specifically modulate the innate immune system, without the risk of off-target effects, opens up entirely novel avenues for the treatment of a number of diseases affecting patients around the world.
Along with several other insights into the innate immune system and its cells, Equaly’s founder established the company in 2016 with a portfolio of patent applications. With many years of experience in both immunology and startups (including the founder’s previous spinoff, ImCyse SA), Equaly is now working to create patient solutions, both in-house and through collaborations, for a wide range of debilitating diseases.
Aims & Ethos
Our Vision
As indicated by our name, Equaly aims to develop therapies accessible to everyone. We strive to cure the very heart of the disease, instead of simply alleviating symptoms.
Our Strategy
Equaly’s strategy is defined by its vision. This means we seek partners who want to collaborate on our main objectives:
- Making use of the huge therapeutic potential of innate immunity
- Eliminating the mechanisms at the basis of disease
- Triggering the body’s own potential for disease control
- Working at the crossroads of immunology, genetics and translational research
- Partnering with patient organizations and both public and private stakeholders
- Being driven by technology
Our Ethics
Equaly’s three main drivers all center on our ultimate goal: helping the patient find a permanent solution to their problem.
01
Innovation and IP
Innovation is our natural driver. It has been fostered by many years spent working in academic institutions and is further illustrated by the solid IP portfolio at Equaly’s disposal.
We protect our innovation with regular patent filings, but also think that innovation should belong to everyone. Therefore, we are open to collaborative efforts with partners who share our vision to help patients in need.
02
Sustainable R&D
When it comes to sustainability, Equaly’s R&D has several advantages over programs targeting adaptive immunity. These include:
- Reduced production costs
Due to the low levels of variability in the innate immune system, biologicals and vaccines created using our platform are valid for the entire patient population. As they can also be tested in vitro, this makes production faster and more cost-effective. - Simpler transition to the clinic
A new generation of biomarkers based on innate immunity, aiming to predict, follow and identify therapeutic responses, should provide confidence and precision in therapeutic decisions. This will consequently reduce the consumption of clinical resources and make for a more refined and safe transition into the clinic. - More efficient clinical trials
Therapeutic interventions based on innate immunity are expected to generate homogenous clinical effects, which should provide the opportunity to reduce the size, number and duration of clinical trials.
03
Cutting-edge technology
Equaly’s credo as a tech-driven company means that up-to-date scientific advances are continuously integrated in our process.
With a special emphasis on genomics and proteomics, our passion for new and innovative technical solutions provides yet another possibility for collaborations with people who share our main vision.
02
Sustainable R&D
When it comes to sustainability, Equaly’s R&D has several advantages over programs targeting adaptive immunity. These include:
- Reduced production costs
Due to the low levels of variability in the innate immune system, biologicals and vaccines created using our platform are valid for the entire patient population. As they can also be tested in vitro, this makes production faster and more cost-effective. - Simpler transition to the clinic
A new generation of biomarkers based on innate immunity, aiming to predict, follow and identify therapeutic responses, should provide confidence and precision in therapeutic decisions. This will consequently reduce the consumption of clinical resources and make for a more refined and safe transition into the clinic. - More efficient clinical trials
Therapeutic interventions based on innate immunity are expected to generate homogenous clinical effects, which should provide the opportunity to reduce the size, number and duration of clinical trials.
03
Cutting-edge technology
Equaly’s credo as a tech-driven company means that up-to-date scientific advances are continuously integrated in our process.
With a special emphasis on genomics and proteomics, our passion for new and innovative technical solutions provides yet another possibility for collaborations with people who share our main vision.
Management
Equaly Management Team (effective January 1, 2021)
MD, PhD, 30 years experience in immunological diseases and translational research, founder of 2 spinoff companies. ...
Equaly Board of Directors
Equaly founder, previously founder, CEO and CSO of ImCyse and of ImNate ...
Michael Jungers obtained his diploma in Political Science from ULB in 2005. He then studied finance and obtained his Certified International Investment Analyst I after that.
He started working in 2006
...
François Boitquin obtained a license in Chemical Sciences from the University of Brussels in 1991, followed by a diploma of Management Engineer from the Institut Solvay in Brussels in 1996, ...
François Louesse holds a diploma in Bio-Engineering from the University of Louvain (2008) and a Master in Management Science from the University of Namur (2012).
From then on, François has occupied
...
Locations
Science has no borders. Our locations in Belgium bring together key players in the Belgian innovation ecosystem and form a bridge to the rest of the EU and beyond.
Our R&D labs are located in the Brussels Life Science Incubator (BLSI) in UCL, Brussels.
Our head offices are in the Center of Entreprises & Innovation (CEI) in Louvain-La-Neuve’s Science Park.
